Purinergic signaling: a novel therapeutic target in depression
Qianqian Cui1, Yunxiao Li1, Shuangqi Gao2
1The First College of Clinical Medical Science, China Three Gorges University, Yichang Central People's Hospital, Yichang, China.
Abstract:
Major depressive disorder, as a common neuropsychiatric disorder, has a complex pathogenesis that has not yet been fully elucidated, posing significant challenges to clinical treatment. In recent years, the role of the purinergic signaling system in the pathophysiological processes of depression has garnered increasing attention. The purinergic signaling primarily involves extracellular purine compounds such as ATP and adenosine, which act as transmitters by binding to their corresponding purine receptors (P1 and P2). Purinergic signaling can participate in depression by affecting the function of astrocytes, neuronal plasticity, and the activity of microglia. This paper systematically reviews the latest research advancements in purinergic signaling related to depression by searching for articles on the PubMed using the keywords 'purinergic' OR 'ATP' OR 'adenosine' and 'depression'. It focuses on the molecular mechanisms of action and discusses the limitations and controversial issues present in current research, aiming to provide new theoretical foundations and treatment strategies for the precise treatment of depression.
Related Concept Videos
G-protein Coupled Receptors
Antidepressant Drugs: MAOIs and Other Agents
G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...
Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
GPCR Desensitization
Depression: Overview


